POLB.F Stock Overview
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
Notes are coming soon
Poolbeg Pharma PLC Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.073|
|52 Week High||UK£0.12|
|52 Week Low||UK£0.073|
|1 Month Change||-36.52%|
|3 Month Change||n/a|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-27.00%|
Recent News & Updates
|POLB.F||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how POLB.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how POLB.F performed against the US Market.
|POLB.F Average Weekly Movement||n/a|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||7.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: Insufficient data to determine POLB.F's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine POLB.F's volatility change over the past year.
About the Company
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
|POLB.F fundamental statistics|
Is POLB.F overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|POLB.F income statement (TTM)|
|Cost of Revenue||UK£0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0062|
|Net Profit Margin||0.00%|
How did POLB.F perform over the long term?See historical performance and comparison